Johnson & Johnson stock holds near record cash flow

Johnson & Johnson (US4781601046) is backed by 2025 sales of $88.8 billion, 2025 adjusted EPS of $10.59, and 2025 free cash flow of $14.7 billion, a mix that keeps the company relevant even on a thin news day. The company also lifted 2026 operating sales guidance to a midpoint of $94.6 billion, according to its 2025 annual report and 2026 outlook materials.

Sales up 5.2%

The 2025 sales figure of $88.8 billion was 5.2% higher than the $84.6 billion reported in 2024, showing that the group still expands at scale. That comparison matters because Johnson & Johnson remains one of the largest health care names in the market, with cash generation and dividend capacity closely tied to top-line growth.

Adjusted EPS reached $10.59 in 2025, while free cash flow totaled $14.7 billion, giving the company room to fund research, manufacturing, and shareholder returns. The combination of growth and cash flow is more useful than a single headline metric because it shows both earnings power and balance-sheet flexibility.

2026 guidance at $94.6 billion

The midpoint of 2026 operating sales guidance is $94.6 billion, which implies 6.5% growth from the 2025 sales base of $88.8 billion. That guide is the current forward marker for the stock, and it gives the market a simple number to test against quarterly execution.

Johnson & Johnson also reported 2025 dividends paid of $11.4 billion, a reminder that the equity case is not driven only by growth, but by sustained capital return as well. For investors, the key question is whether the company can keep converting low-double-digit earnings power into higher cash flow.

Darzalex still matters

Darzalex remains one of the company’s most important medicines, and Johnson & Johnson has continued to lean on its oncology portfolio to support group growth. Product concentration matters because a single franchise can help offset slower areas elsewhere in the portfolio.

The broader health care mix still includes pharmaceuticals, medtech, and consumer-facing legacy assets, but the article-level relevance today sits in the 2025-2026 numbers: $88.8 billion in sales, $10.59 in adjusted EPS, and $94.6 billion at the midpoint of 2026 guidance. Those figures are the clearest way to judge momentum without relying on speculation.

Cash flow and yield

Free cash flow of $14.7 billion in 2025 gives Johnson & Johnson another layer of support, because cash matters when the market re-rates defensive health care names. The company also paid $11.4 billion in dividends in 2025, which shows the cash return profile remains a central part of the equity story.

If the company converts the 2026 sales guide into sustained earnings and cash flow, the stock will likely continue to be judged on resilience rather than rapid growth. The key reading remains the same: stable growth, durable cash generation, and a large pharmaceutical base.